In 1984, Granules India was formed as Triton Laboratories to produce Paracetamol API at our Bonthapally facility in Hyderabad.
In 1987, Triton became the second Indian company to export pharmaceutical products to the U.S.
In 1990, Triton opened its second manufacturing facility at Jeedimetla to produce multiple APIs.
In 1991, Triton laboratories was incorporated into Granules India Limited.
In 1993, Granules establishedits first PFI facility at Jeedimetla.
In 1995, Granules became a public company, after having initial public offerings on the Bombay and Hyderabad Stock Exchanges.
In 2003, Granules opened a new large volume PFI facility in Gagillapur.
In 2003, Granules setup a wholly owned subsidiary, Granules USA, for marketing in the US
In 2005, a new Paracetamol plant was built in Bonthapally, Hyderabad.
In 2006, Granules formed a joint venture with Hubei Biocause to make and sell Ibuprofen API.
In 2008, Granules entered into the Finished Dosage segment.
In 2010, Granules received US FDA approval for its first Abbreviated New Drug Application (ANDA).
In 2011, Granules-OmniChem, a joint venture with Ajinomoto OmniChem was established to venture into Contract Research and Manufacturing Services (CRAMS) business.
In 2013, Granules established a 10,000 sq. foot R&D facility in Pragathi Nagar, Hyderabad.
In 2014, Granules acquired Auctus Pharma
In 2014, Granules setup a wholly-owned subsidiary in the US; Granules Pharmaceutical to focus on formulation R&D.
In 2015, Granules entered the Over the Counter business in the US through Granules Consumer Healthcare.